Krystal Biotech Q3 Estimates Point to 29.4% Revenue Growth
Photo: TokenPost
Krystal Biotech (KRYS) has a third-quarter revenue estimate of $126.54 million, 29.4% above the year-earlier quarter. Earnings per share are estimated at $1.92, a 27.8% decline from a year earlier. The company is scheduled to release results before U.S. markets open Monday, Nov. 2. John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.
Source: TokenPost
